Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 138-147

  Schenker, Howard ^a   Maloney, Susan ^b   Liss, Charles ^b   Gormley, Glenn ^b   Hartenbaum, David ^b,c  

^a Private Practice   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NONE   (United States)

Author keywords

Glaucoma; Ocular hypertension; Timolol maleate ophthalmic gel forming solution; Timolol maleate solution

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; GELRITE; TIMOLOL MALEATE;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EYE INFLAMMATION; GEL; HEART RATE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL IMPAIRMENT;

EID: 0032970777     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88274-0     Document Type: Article

References (7)

1. 1. Greaves JL, Wilson CG, Rozier A, et al. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res. 1990;9:415-420.
2. 2. Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite: A novel ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm. 1989;57:163-168.
3. 3. Nelson MD, Bartlett JD, Corliss D, Voce M. Ocular tolerability of timolol in Gelrite in young glaucoma patients. J Am Optom Assoc. 1996;67:659-663.
4. 4. Hommer A, Nowak A, Huber-Spitzy V. A multidose, double masked, parallel treatment controlled multicenter study of 0.25% timolol in Gelrite (TG) once daily vs. 0.25% timolol solution (TS) twice daily. German Study Group. Ophthalmologe. 1995;92:546-549. In German.
5. 5. Shedden AH, Laibovitz RA, Repass R, et al. Twenty-four hour diurnal variation of IOP following administration of Timoptic-XE qd as compared to Timoptic bid. Invest Ophthalmol Vis Sci. 1993;34(Suppl):927. Abstract.
6. 6. Shedden A, Laurence J, Tipping R, et al. Multiclinic, double-masked study of 0.5% Timoptic-XE (TXE) once daily versus 0.5% Timoptic (TS) twice daily. Ophthalmology. 1993;100(Suppl):#55. Abstract.
7. 7. Shedden AH, Laurence JK, Sharma D, et al. Switching patients from 0.5% Timoptic (TS) twice daily to 0.5% Timoptic-XE (TXE) once daily. Ophthalmology. 1994; 101(Suppl):#233. Abstract.